

CHDI Foundation Enroll-HD Study

eClinicalGPS & ClinCard System



At a Glance

Situation

- Global Huntington's Disease study requires site and patient payment technologies to handle payments across over 230 sites in 29 countries and four continents.

Solution

- Greenphire's eClinicalGPS and ClinCard System technologies implemented on a study-wide basis.

Results

- Worldwide research sites and trial participants receive automated, real-time payments in local currencies.
- CHDI reduces payment-related administration by up to 90%.
- CHDI achieves unprecedented tracking capability to simplify Sunshine Act data aggregation.

Solutions Provided

ClinCard



eClinicalGPS



“As a global study, Enroll-HD needs a set of technologies that can benefit our sites and patients around the world.”

Joseph Giuliano

Director of Clinical Operations, CHDI

The Situation

The Enroll-HD study is a longitudinal clinical observational study for Huntington's Disease patients, executed by CHDI Foundation, the leading biomedical research organization exclusively dedicated to developing therapies for HD. The study includes sites in North America, Latin America, Europe, and Australia, and over 230 sites in total. This diverse and international study offers excellent research parameters, but poses a unique challenge to clinical operations and finance team members in managing local compliance and foreign exchange complications across dozens of countries with varying local laws and regulations.

CHDI's traditional clinical payment method of manually-issued paper checks is ill-equipped to handle the complexity of the Enroll-HD study. Calculating, delivering, and tracking global site and patient payments creates an inordinate administrative burden for both CHDI's study teams and research site personnel which rely on fast, accurate site payments and which must themselves manage hundreds of manual patient travel reimbursement payments. Limited tracking and data aggregation capabilities further strain the clinical payment process and complicate payment data aggregation for Sunshine Act disclosures.

The Solution

Greenphire's clinical payment technologies are implemented to automate both site and patient payment processes and enable CHDI to seamlessly calculate, deliver, and track each of the Enroll-HD study's thousands of payment transactions.

CHDI utilizes the eClinicalGPS platform to automatically manage site and investigator payments in local currency across each of the Enroll-HD study's 29 countries. The ClinCard System is implemented to deliver real-time electronic travel expense payments to study participants in local currency.

“Enroll-HD will be an important research platform for the HD research community, industry partners, and investigators developing therapies for HD that will improve outcomes for patients, said Joseph Giuliano, Director of Clinical Operations at CHDI. “As a global study, Enroll-HD needs a set of technologies that can benefit all of our sites around the world, and throughout our planning stages the Greenphire team has shown they are capable of delivering efficient payment solutions that meet our needs.”

Both the eClinicalGPS and ClinCard System technologies are introduced at the study's initial investigator meetings and widely embraced by investigators and site coordinators.

“Greenphire makes CHDI’s global payments faster, simpler, and more secure so that our study teams can focus their energy on our patients, our sites, and the clinical success of our studies.”

Robi Blumenstein
President, CHDI Foundation



The Results

The Enroll-HD study offers excellent research parameters within which to leverage Greenphire’s global solutions to drive value and efficiency for CHDI, participating research sites, and study participants.

A joint analysis by Greenphire and CHDI executives estimates that integrating Greenphire’s payment technology platforms will reduce costs associated with managing and delivering clinical site and patient payments by up to 90% when compared with manual paper-based processes, with overall cost savings exceeding \$200,000.

The eClinicalGPS also allows CHDI to achieve unprecedented transparency into the Enroll-HD study’s financial health. Through a series of customized financial analytics and reports, CHDI to track, aggregate, and analyze study payment data and simplify Sunshine Act disclosures. The eClinicalGPS’ reporting capability includes:

- *Automated monthly accruals on a global basis*
- *Automated expense forecasting*
- *Historic budget data for contract negotiation*
- *Historic study expense data for strategic planning*
- *Foreign exchange metrics and analysis*
- *Sunshine Act data aggregation*

CHDI executives further expect the ClinCard’s real-time payment deliverability to significantly impact retention of the study’s large body of patients. Through the ClinCard System, CHDI offers study participants a reloadable branded debit card, which can be automatically loaded with travel reimbursement or stipend payments as patients complete office visits or other study milestones. By avoiding the delays inevitable to manual paper check reimbursement, CHDI tangibly enhances the patient experience in the clinical environment, with a corresponding increase in patient retention of an estimated 11.7%.

CHDI President Robi Blumenstein commented on the decision to automate Enroll-HD’s global payment processes: “At CHDI our mission is to develop drugs that will make a difference in HD patients’ lives in the quickest possible time,” he said. “Greenphire makes CHDI’s global payments faster, simpler, and more secure so that our study teams can focus their energy on our patients, our sites, and the clinical success of our studies.”

For More Information:

www.greenphire.com
sales@greenphire.com
215.948.9251